Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 13/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11191170 | 0.86 | VNN1 (0.64) | VNN1CYP2C19PTGS1KCNH2 | |
| SCHEMBL574239 | 0.85 | VNN1 (0.63) | VNN1CYP2C19 | |
| Pantothenic Acid, Racemic SCHEMBL1261508 | 0.81 | PTGS1 (0.58) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid SCHEMBL1261506 | 0.81 | PTGS1 (0.58) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid, Racemic SCHEMBL1835339 | 0.79 | PTGS1 (0.62) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid SCHEMBL7016631 | 0.77 | PTGS1 (0.67) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid SCHEMBL21547 | 0.77 | PTGS1 (0.67) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid, Racemic SCHEMBL21114380 | 0.77 | PTGS1 (0.67) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid, Racemic SCHEMBL5437 | 0.77 | PTGS1 (0.67) | VNN1PTGS1KCNH2 | |
| Pantothenic Acid SCHEMBL14126322 | 0.77 | PTGS1 (0.67) | VNN1PTGS1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-20220347126-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11406607-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021203136-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-20170348254-A1 | MICROPARTICLES | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20170348253-A1 | Treatment of Drug-Resistant Microbial Infections | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-3976781-A | SULFUR CONTAINING AMINES | L'OREAL (FR) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | VNN1 3652/4885CYP2C19 4279/4885PTGS1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.